Mano MS - Search Results

1

Novel cytotoxic drugs: old challenges, new solutions.

Ismael GF, Rosa DD, Mano MS, Awada A. Ismael GF, et al. Among authors: mano ms. Cancer Treat Rev. 2008 Feb;34(1):81-91. doi: 10.1016/j.ctrv.2007.08.001. Epub 2007 Oct 1. Cancer Treat Rev. 2008. PMID: 17905518 Review.

2

The pipeline of new anticancer agents for breast cancer treatment in 2003.

Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, Piccart MJ. Awada A, et al. Crit Rev Oncol Hematol. 2003 Oct;48(1):45-63. doi: 10.1016/s1040-8428(03)00171-9. Crit Rev Oncol Hematol. 2003. PMID: 14585483 Review.

3

New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.

Awada A, Mano M, Hendlisz A, Piccart M. Awada A, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):53-60. doi: 10.1586/14737140.4.1.53. Expert Rev Anticancer Ther. 2004. PMID: 14748657 Review.

4

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M. Mano MS, et al. Gynecol Oncol. 2004 Mar;92(3):887-95. doi: 10.1016/j.ygyno.2003.12.010. Gynecol Oncol. 2004. PMID: 14984957

5

Primary chemotherapy for breast cancer: the evidence and the future.

Mano MS, Awada A. Mano MS, et al. Ann Oncol. 2004 Aug;15(8):1161-71. doi: 10.1093/annonc/mdh302. Ann Oncol. 2004. PMID: 15277254 Free article. Review.

6

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M. Mano MS, et al. Breast. 2004 Aug;13(4):347-9. doi: 10.1016/j.breast.2003.11.009. Breast. 2004. PMID: 15325672

7

Remaining controversies in the upfront management of advanced ovarian cancer.

Mano MS, Awada A, Minisini A, Atalay G, Lago LD, Cardoso F, Piccart M. Mano MS, et al. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):707-20. doi: 10.1111/j.1048-891X.2004.014502.x. Int J Gynecol Cancer. 2004. PMID: 15361178 Review.

8

Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?

Mano MS, Awada A, Kerr J, Canney P. Mano MS, et al. Cancer Treat Rev. 2005 Apr;31(2):69-78. doi: 10.1016/j.ctrv.2004.11.001. Epub 2005 Jan 22. Cancer Treat Rev. 2005. PMID: 15847977 Review.

9

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M. Awada A, et al. Br J Cancer. 2005 May 23;92(10):1855-61. doi: 10.1038/sj.bjc.6602584. Br J Cancer. 2005. PMID: 15870716 Free PMC article. Clinical Trial.

10

Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.

Mano M. Mano M. Cancer Treat Rev. 2006 Apr;32(2):106-18. doi: 10.1016/j.ctrv.2005.12.008. Epub 2006 Feb 13. Cancer Treat Rev. 2006. PMID: 16473470 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters